Cargando…
Gastrointestinal stromal tumor and its targeted therapeutics
Over the past 60 years, investigators of basic science, pathology, and clinical medicine have studied gastrointestinal stromal tumor (GIST) and made minor advances in patient care. Recent discoveries have led to an understanding of the biological role of KIT and platelet-derived growth factor recept...
Autores principales: | Dupart, Jheri, Zhang, Wei, Trent, Jonathan C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013395/ https://www.ncbi.nlm.nih.gov/pubmed/21527063 http://dx.doi.org/10.5732/cjc.011.10062 |
Ejemplares similares
-
Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro
por: Dupart, Jheri J, et al.
Publicado: (2009) -
Immunotherapy Strategies for Gastrointestinal Stromal Tumor
por: Arshad, Junaid, et al.
Publicado: (2021) -
Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
por: Masucci, Maria Teresa, et al.
Publicado: (2023) -
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability
por: Lee, Donna M., et al.
Publicado: (2022) -
Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)